loader
Please Wait
Applying Filters...

Others: AFFiRiS and Frontier Biotechnologies announce license agreement for AFFITOPE®AT04, an active immunotherapy targeting PCSK9 to treat hypercholesterolemia, in Greater China - Frontier Biotechnologies

Xls
Menu